EGFR and non-small cell lung carcinoma: This could be explained by the high prevalence of EGFR exon 20-ins, which are resistant to these drugs [9], but are more susceptible to new target therapies, including amivantamab [11] and mobocertinib [12], recently studied and approved in NSCLC.